Literature DB >> 34918299

Establishment of In Vivo Ovarian Cancer Mouse Models Using Intraperitoneal Tumor Cell Injection.

Sonam Mittal1, Prachi Gupta1, Pradeep Chaluvally-Raghavan1,2, Sunila Pradeep3,4.   

Abstract

Mouse models-xenograft models, syngeneic models (directly implanted or chemically or virally induced), and genetically engineered mice (including transgenic and knockout methods) are invaluable for preclinical studies of ovarian cancer as they recapitulate the structures and microenvironments of tumors, which in vitro studies are unable to accomplish.This chapter describes the methodology and approaches for generating various murine models currently employed in ovarian cancer research. It covers the implantation of cells from ovarian cancer cell lines into mice by intraperitoneal injection.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  In vivo models; Ovarian cancer; Syngeneic models; Xenograft models

Mesh:

Year:  2022        PMID: 34918299     DOI: 10.1007/978-1-0716-1956-8_16

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  12 in total

1.  Mouse xenograft models vs GEM models for human cancer therapeutics.

Authors:  Ann Richmond; Yingjun Su
Journal:  Dis Model Mech       Date:  2008 Sep-Oct       Impact factor: 5.758

2.  Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.

Authors:  Ludmila Szabova; Chaoying Yin; Sujata Bupp; Theresa M Guerin; Jerome J Schlomer; Deborah B Householder; Maureen L Baran; Ming Yi; Yurong Song; Wenping Sun; Jonathan E McDunn; Philip L Martin; Terry Van Dyke; Simone Difilippantonio
Journal:  Cancer Res       Date:  2012-05-22       Impact factor: 12.701

Review 3.  Latest research and treatment of advanced-stage epithelial ovarian cancer.

Authors:  Robert L Coleman; Bradley J Monk; Anil K Sood; Thomas J Herzog
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

4.  Ovarian cancer statistics, 2018.

Authors:  Lindsey A Torre; Britton Trabert; Carol E DeSantis; Kimberly D Miller; Goli Samimi; Carolyn D Runowicz; Mia M Gaudet; Ahmedin Jemal; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2018-05-29       Impact factor: 508.702

5.  The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin.

Authors:  Jeffrey D Seidman; Iren Horkayne-Szakaly; Moutaz Haiba; Charles R Boice; Robert J Kurman; Brigitte M Ronnett
Journal:  Int J Gynecol Pathol       Date:  2004-01       Impact factor: 2.762

6.  Epidemiology of ovarian cancer: a review.

Authors:  Brett M Reid; Jennifer B Permuth; Thomas A Sellers
Journal:  Cancer Biol Med       Date:  2017-02       Impact factor: 4.248

7.  Ovarian cancer mouse models: a summary of current models and their limitations.

Authors:  Miranda Y Fong; Sham S Kakar
Journal:  J Ovarian Res       Date:  2009-09-28       Impact factor: 4.234

Review 8.  New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches.

Authors:  P Rescigno; I Cerillo; R Ruocco; C Condello; S De Placido; M Pensabene
Journal:  Biomed Res Int       Date:  2013-08-25       Impact factor: 3.411

Review 9.  Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment.

Authors:  Jeremy Chien; Rui Kuang; Charles Landen; Viji Shridhar
Journal:  Front Oncol       Date:  2013-09-24       Impact factor: 6.244

Review 10.  Recent technological advances in using mouse models to study ovarian cancer.

Authors:  Carrie Danielle House; Lidia Hernandez; Christina Messineo Annunziata
Journal:  Front Oncol       Date:  2014-02-13       Impact factor: 6.244

View more
  1 in total

1.  PHGDH Inhibitor CBR-5884 Inhibits Epithelial Ovarian Cancer Progression via ROS/Wnt/β-Catenin Pathway and Plays a Synergistic Role with PARP Inhibitor Olaparib.

Authors:  Xiaocui Zhang; Meige Sun; Yisheng Jiao; Bei Lin; Qing Yang
Journal:  Oxid Med Cell Longev       Date:  2022-09-05       Impact factor: 7.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.